Madrigal Pharmaceuticals, Inc. MDGL Business Segments — Product revenue, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s business segments — product revenue, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s business segments — product revenue, net?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported business segments — product revenue, net of $311.34M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s business segments — product revenue, net changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s business segments — product revenue, net increased by 126.8% year-over-year, from $137.25M to $311.34M.
- What does business segments — product revenue, net mean?
- The total money earned from selling products after deducting discounts and returns.
- How do you interpret business segments — product revenue, net?
- An increase indicates successful commercialization and growing market demand for the company's drugs.
- How does business segments — product revenue, net compare across companies?
- Standard across all biopharmaceutical companies reporting commercial product sales.